A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled study to assess the Efficacy and Safety of ENDO3285 for Prevention or Delay to Onset of Severe Oral Mucositis in Patients with Head and Neck Cancer Receiving Chemoradiotherapy

Grants and Contracts Details

StatusFinished
Effective start/end date4/25/086/30/09

Funding

  • Endo Pharmaceutical Inc: $1,800.00